396
Participants
Start Date
April 30, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
GSK372475
daily administration during the 10-week treatment phase
venlafaxine
daily administration during the 10-week treatment phase
placebo
daily administration during the 10-week treatment phase
GSK Investigational Site, Vereeniging
GSK Investigational Site, Epping
GSK Investigational Site, Heidelberg West
GSK Investigational Site, Liège
GSK Investigational Site, Kippa-Ring
GSK Investigational Site, Auchenflower
GSK Investigational Site, Mont-Godinne
GSK Investigational Site, Somerset West
GSK Investigational Site, Somerset West
GSK Investigational Site, Observatory ,Cape Town
GSK Investigational Site, Burgas
GSK Investigational Site, Varna
GSK Investigational Site, Tallinn
GSK Investigational Site, Schwerin
GSK Investigational Site, Turku
GSK Investigational Site, Westerstede
GSK Investigational Site, Toulouse
GSK Investigational Site, Arcachon
GSK Investigational Site, Tartu
GSK Investigational Site, Võru
GSK Investigational Site, Kuopio
GSK Investigational Site, Paris
GSK Investigational Site, Munich
GSK Investigational Site, Unterhaching
GSK Investigational Site, Würzburg
GSK Investigational Site, Tirupati
GSK Investigational Site, Bangalore
GSK Investigational Site, Chennai
GSK Investigational Site, Edmonton
GSK Investigational Site, Kelowna
GSK Investigational Site, Sydney
GSK Investigational Site, Sydney
GSK Investigational Site, Burlington
GSK Investigational Site, Mississauga
GSK Investigational Site, Montreal
GSK Investigational Site, Hyderabad
GSK Investigational Site, Bialystok
GSK Investigational Site, Gdansk
GSK Investigational Site, Lublin
GSK Investigational Site, Skorzewo
GSK Investigational Site, Bratislava
GSK Investigational Site, Michalovce
Lead Sponsor
GlaxoSmithKline
INDUSTRY